The FDA granted breakthrough therapy designation to Pfizer's palbociclib as possible treatment for breast cancer patients. The decision was based on preliminary midstage trial results showing palbociclib's efficacy in improving median progression free survival in patients, in combination with letrozole.
Pfizer wins fast-track status for breast cancer drug palbociclib
SmartBrief Job Listings for Health Care
|Chief Financial Officer||
B. E. Smith
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|